Research output per year
Research output per year
Personal profile
Research interests
Neuromuscular Disorders
Clinical interests
Clinical neurology, neuromuscular disease, neuroimmunology, glycolipids, proteoglycans, aging and the nervous system, history of neurology, myopathy, neuropathy, weakness, myasthenia, muscle, nerve, numbness, sensory loss, pain, fatigue, muscular dystrophy, neuro muscular.More Information on the Neuromuscular Disease Center
Fingerprint
Dive into the research topics where Alan Pestronk is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Assessing the Relationship of Patient Reported Outcome Measures With Functional Status in Dysferlinopathy: A Rasch Analysis Approach
Mayhew, A. G., James, M. K., Moore, U., Sutherland, H., Jacobs, M., Feng, J., Lowes, L. P., Alfano, L. N., Muni Lofra, R., Rufibach, L. E., Rose, K., Duong, T., Bello, L., Pedrosa-Hernández, I., Holsten, S., Sakamoto, C., Canal, A., Sánchez-Aguilera Práxedes, N., Thiele, S., Siener, C., & 25 others, Mar 10 2022, In: Frontiers in Neurology. 13, 828525.Research output: Contribution to journal › Article › peer-review
Open Access -
Cardiac and pulmonary findings in dysferlinopathy: A 3-year, longitudinal study
The Jain COS Consortium, May 2022, In: Muscle and Nerve. 65, 5, p. 531-540 10 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Development of a model-based clinical trial simulation platform to optimize the design of clinical trials for Duchenne muscular dystrophy
the Cooperative International Neuromuscular Research Group investigators and Duchenne Regulatory Science Consortium members, Mar 2022, In: CPT: Pharmacometrics and Systems Pharmacology. 11, 3, p. 318-332 15 p.Research output: Contribution to journal › Article › peer-review
Open Access5 Scopus citations -
Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy
Statland, J. M., Campbell, C., Desai, U., Karam, C., Díaz-Manera, J., Guptill, J. T., Korngut, L., Genge, A., Tawil, R. N., Elman, L., Joyce, N. C., Wagner, K. R., Manousakis, G., Amato, A. A., Butterfield, R. J., Shieh, P. B., Wicklund, M., Gamez, J., Bodkin, C., Pestronk, A., & 9 others, Jul 2022, In: Muscle and Nerve. 66, 1, p. 50-62 13 p.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
Randomized Phase 2 Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease
Thomas, F. P., Brannagan, T. H., Butterfield, R. J., Desai, U., Habib, A. A., Herrmann, D. N., Eichinger, K. J., Johnson, N. E., Karam, C., Pestronk, A., Quinn, C., Shy, M. E., Statland, J. M., Subramony, S. H., Walk, D., Stevens-Favorite, K., Miller, B., Leneus, A., Fowler, M., Van De Rijn, M., & 1 others, Jun 7 2022, In: Neurology. 98, 23, p. E2356-E2367Research output: Contribution to journal › Article › peer-review
1 Scopus citations